+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Peritoneal Cancer - Pipeline Insight, 2021

  • ID: 5306348
  • Clinical Trials
  • October 2021
  • Region: Global
  • 60 Pages
  • DelveInsight

FEATURED COMPANIES

  • APIM Therapeutics
  • Boryung Pharmaceutical
  • Corcept Therapeutics
  • Jiangsu HengRui Medicine
  • Mucpharm Pty Ltd
  • Pfizer
This “Peritoneal cancer - Pipeline Insight, 2021” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Peritoneal cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Peritoneal cancer Understanding


Peritoneal cancer: Overview


The peritoneum is a membrane that covers the inner lining of the abdominal cavity and the organs lying in there. It helps to support these organs and contains the blood vessels and nerves that supply them. The space in the abdominal cavity covered by the peritoneum is known as the peritoneal cavity. Peritoneal metastases refer to cancer that has spread to the peritoneum from other organs. When cancer spreads from other organs, it is considered advanced and denote Stage IV disease in most cases. Complications related to peritoneal metastases include: Ascites: Peritoneal metastases tend to produce fluid in the abdomen, known as ascites, which causes abdominal distension, Intestinal obstruction: Peritoneal metastases may cause blockage of the intestines, Hydronephrosis: The kidney ureters may be blocked by peritoneal metastases. This may affect the kidney function. The diagnosis of peritoneal cancer can be difficult. Imaging (such as CT or MRI scans), needle drainage of ascitic fluid for analysis, keyhole surgery, or a combination of these may be required to confirm the diagnosis of peritoneal metastases. Treatment of peritoneal cancer depends on the stage of cancer, where the primary tumor started, how far it has spread, and the patient's overall health. Surgery, chemotherapy, radiotherapy, and targeted therapy.

"Peritoneal cancer - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Peritoneal cancer pipeline landscape is provided which includes the disease overview and Peritoneal cancer treatment guidelines. The assessment part of the report embraces, in depth Peritoneal cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peritoneal cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights


The companies and academics are working to assess challenges and seek opportunities that could influence Peritoneal cancer R&D. The therapies under development are focused on novel approaches to treat/improve Peritoneal cancer.

Peritoneal cancer Emerging Drugs Chapters


This segment of the Peritoneal cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Peritoneal cancer Emerging Drugs


Mirvetuximab soravtansine: ImmunoGen


Mirvetuximab soravtansine (IMGN853) is a first-in-class ADC comprising a folate receptor alpha (FRα)-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin-targeting agent to kill the targeted cancer cells. The drug is being studied in phase III stage of development for the treatment of patients with peritoneal cancer.

Pembrolizumab: Merck & Co


Pembrolizumab is a highly selective humanized monoclonal IgG4 antibody directed against the PD-1 receptor on the cell surface. The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells. Pembrolizumab is a medication used in the management and treatment of various oncologic conditions. It is in the cancer immunotherapy class of drugs. Currently it is being evaluated in Phase III stage of development for the treatment of peritoneal cancer.

DCVAC/OvCa: SOTIO


SOTIO's DCVAC Program is a cell therapy platform designed to improve efficacy compared to earlier generations of dendritic cell therapies by targeting multiple antigens and applying an immune-stimulatory technique. SOTIO has created this vertically integrated, personalized cell therapy platform to enable the efficient manufacturing of product doses for one year of treatment at commercially attractive costs. It is currently being evaluated in Phase III clinical trial to treat peritoneal cancer.

PF-06873600: Pfizer


PF-06873600 selectively targets, binds to and inhibits the activity of CDKs. Inhibition of these kinases leads to cell cycle arrest, induction of apoptosis and inhibition of tumor cell proliferation. The drug is being investigated in Phase II stage of development for the treatment of peritoneal cancer, HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, and Fallopian Tube Cancer.

Peritoneal cancer: Therapeutic Assessment


This segment of the report provides insights about the different Peritoneal cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Peritoneal cancer


There are approx. 50+ key companies which are developing the therapies for Peritoneal cancer. The companies which have their Peritoneal cancer drug candidates in the most advanced stage, i.e. Phase III include, ImmunoGen.

Phases


This report covers around 50+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Peritoneal cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Peritoneal cancer: Pipeline Development Activities


The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Peritoneal cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peritoneal cancer drugs.

Peritoneal cancer Report Insights

  • Peritoneal cancer Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Peritoneal cancer Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered


Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Peritoneal cancer drugs?
  • How many Peritoneal cancer drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peritoneal cancer?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Peritoneal cancer therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Peritoneal cancer and their status?
  • What are the key designations that have been granted to the emerging drugs?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • APIM Therapeutics
  • Boryung Pharmaceutical
  • Corcept Therapeutics
  • Jiangsu HengRui Medicine
  • Mucpharm Pty Ltd
  • Pfizer
Introduction

Executive Summary

Peritoneal cancer: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
  • Comparative Analysis
Mirvetuximab soravtansine: ImmunoGen
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
PF-06873600: Pfizer
  • Product Description
  • Research and Development
  • Product Development Activities
Early stage products (Phase I/II)
  • Comparative Analysis
ART0380: Artios Pharma
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Peritoneal cancer Key Companies

Peritoneal cancer Key Products

Peritoneal cancer- Unmet Needs

Peritoneal cancer- Market Drivers and Barriers

Peritoneal cancer- Future Perspectives and Conclusion

Peritoneal cancer Analyst Views

Peritoneal cancer Key Companies

Appendix

List of Tables
Table 1 Total Products for Peritoneal cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Peritoneal cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Pfizer
  • ImmunoGen
  • Boryung Pharmaceutical
  • OncoQuest
  • Janssen Research & Development
  • OncXerna Theraputics
  • Merck & Co
  • Sotio a.s.
  • AstraZeneca
  • Lee's Pharmaceutical
  • Corcept Therapeutics
  • GlaxoSmithKline
  • Pfizer
  • Bristol-Myers Squibb
  • Seagen Inc.
  • CSPC ZhongQi Pharmaceutical Technology
  • Context Therapeutics
  • Medivation, Inc.
  • Astex Pharmaceuticals
  • APIM Therapeutics
  • Celsion
  • Syndax Pharmaceuticals
  • ImmunoVaccine Technologies
  • Regeneron Pharmaceuticals
  • Mucpharm Pty Ltd
  • Artios Pharma
  • Sumitomo Dainippon Pharma
  • OncoQuest Pharma
  • Genelux Corporation
  • Y-mAbs Therapeutics
  • PGEN Therapeutics
  • Jiangsu HengRui Medicine
Note: Product cover images may vary from those shown
Adroll
adroll